28/01/2025 – Presentation of the AB Science webcast held on January 28, 2025 Download PDF Post navigationPreviousPrevious post:Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CETNextNext post:Summary of the webcast held on January 28, 2025Related PostsEuropean Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseApril 14, 2025Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025Summary of the webcast held on January 28, 2025January 29, 2025Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CETJanuary 24, 2025AB Science will participate in the Biomed Forum investors conferenceJanuary 22, 2025
European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseApril 14, 2025
Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025
